accountNEW BRUNSWICK, N.J. (TheStreet) -- Johnson & Johnson(JNJ) may be on the hook to pay $1 billion to federal prosecutors to resolve allegations of improper marketing and promotion of antipsychotic drug Risperdal for unapproved uses...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to J&J's Risperdal Charges Could Cost $1 Billion
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account